News

CvilleBioHub Report Highlights Impact from Jobs, Capital and Innovation

CvilleBioHub’s first Industry Report on the scope of the biotechnology industry in the CvilleBioHub Region (CBR) highlights the growing economic and societal impact from jobs, capital and innovation. The report details the more than 65 companies emerging and growing within the region and shows activity and investment by sector, from medical devices and therapeutics to biomanufacturing and health tech.

“The CvilleBioHub Region is a thriving ecosystem with access to capital, infrastructure and a growing, highly skilled workforce,” said Nikki Hastings, executive director of CvilleBioHub. “This is a diverse industry with multiple sectors represented and we help drive the dollars in our regional economy with $1.2 billion in total economic activity.”

Key findings from the first-of-its kind report

Talent: The CBR employs 1,950 people with high-paying, career ladder jobs totaling $350 million in wages. For every biotech job in the region, 1.7 more jobs are created.
Impact: The CBR contributes to a total of 5,261 jobs and $1.2B in economic activity, which is above average compared to other industries in the region.
Capital: Companies have financed their efforts through more than $330M in support, which includes $276M in private, angel and venture capital investments and $54M of nondilutive grant awards.

Infrastructure and Facilities: The industry occupies 839,800 square feet of space at an average of $25 per square foot with a growing need for specialty wet lab space.
Mergers & Acquisitions: Nine major acquisitions or Initial Public Offerings (IPO) were announced between 2008-2019, offering a return on investment for early participating angels and validating the successful entrepreneurial talent in the CBR.

“This comprehensive industry report shows a building of and formalization of a community with all the components to develop a true BioHub,” said Bob Creeden, managing director of UVA LVG Seed Fund, a CvilleBioHub partner and active early stage investor in Charlottesville biotech companies. “The successes chronicled to date will help the region attract funding and the demonstrated growth will attract top leadership talent.”

The report also shows how the CBR is attractive from an economic development vantage point, with key partnerships in higher education, local government and industry, and results in high economic multipliers, according to Jim Cheng, GO Virginia Region 9 Council Chair.

“Biotechnology is a strength for our state and provides an opportunity to diversify industries in Virginia,” Cheng said. “This is the first time we have seen an initiative so directed and showcasing a critical mass of community and industry.”

Recent News

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …

10/28/2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced that it has changed its corporate name to Azora Therapeutics, Inc. The company’s common stock is expected to commence trading on The Nasdaq Capital Market under the new ticker symbol “AZR” on October 29, 2026. Azora has also launched …

10/28/2026

U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …